Inflammatory Pseudotumor of the Spleen in a Patient With Psoriatic Arthritis: A Diagnostic Challenge in the COVID-19 Era
- PMID: 39651014
- PMCID: PMC11622730
- DOI: 10.7759/cureus.73121
Inflammatory Pseudotumor of the Spleen in a Patient With Psoriatic Arthritis: A Diagnostic Challenge in the COVID-19 Era
Abstract
The baseline inflammatory microenvironment in various organs of patients, which is shaped by pre-existing conditions and circulating drugs at the time before viral antigen exposure, may affect the severity of coronavirus disease-19 (COVID-19) infection and the nature of its complications. Inflammatory pseudotumor (IPT) of the spleen may represent one such complication that merits further investigation. We describe the case of a patient, who was under long-term treatment with a tumor necrosis factor inhibitor (TNFi), for psoriatic arthritis (PsA) and developed an inflammatory mass in the spleen, accompanied by systemic manifestations. This occurred with a history of four doses of nucleoside-modified messenger RNA (modRNA) vaccination for COVID-19 and shortly after a SARS coronavirus-2 (SARS-CoV-2) infection. Histologic examination of the splenectomy specimen supported by a large array of immunohistochemical stains and subsequent clinicopathological correlation indicated the diagnosis of splenic IPT in an immunologically altered background, due to modifying medication, immunization, and infection. Our case speculates that IPT may represent an adverse event related to immunogenicity of SARS-CoV-2, following antigen exposure (at first by sequential modRNA COVID-19 vaccinations and additionally by natural infection), despite the potentially protective effect of treatment with a TNFi.
Keywords: covid-19; disease modifying anti-rheumatic drugs; inflammatory pseudotumor; mrna-based vaccine; psoriatic arthritis; rheumatic disease; sars-cov-2; spleen; tumor necrosis factor-α(tnf-α) inhibitor.
Copyright © 2024, Iliadis et al.
Conflict of interest statement
Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Figures


Similar articles
-
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors.RMD Open. 2022 Jan;8(1):e001847. doi: 10.1136/rmdopen-2021-001847. RMD Open. 2022. PMID: 34987092 Free PMC article.
-
Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors.Clin Exp Rheumatol. 2023 Jan;41(1):166-169. doi: 10.55563/clinexprheumatol/hptln9. Epub 2022 Nov 24. Clin Exp Rheumatol. 2023. PMID: 36441661
-
New-Onset Psoriatic Arthritis Following COVID-19 mRNA Vaccination in a Psoriatic Patient Under Anti-tumor Necrosis Factor Alpha Biologic Treatment: What Now?Cureus. 2023 Dec 18;15(12):e50723. doi: 10.7759/cureus.50723. eCollection 2023 Dec. Cureus. 2023. PMID: 38234927 Free PMC article.
-
Modified mRNA-Based Vaccines Against Coronavirus Disease 2019.Cell Transplant. 2022 Jan-Dec;31:9636897221090259. doi: 10.1177/09636897221090259. Cell Transplant. 2022. PMID: 35438579 Free PMC article. Review.
-
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.Expert Rev Clin Immunol. 2020 Feb;16(2):207-228. doi: 10.1080/1744666X.2019.1705785. Epub 2020 Jan 11. Expert Rev Clin Immunol. 2020. PMID: 31852268 Review.
References
-
- Inflammatory pseudotumour (plasma cell granuloma) of lung, liver and other organs. Anthony PP. Histopathology. 1993;23:501–503. - PubMed
-
- Clinical features and correct diagnosis of macrophage activation syndrome. Cron RQ, Davi S, Minoia F, Ravelli A. Expert Rev Clin Immunol. 2015;11:1043–1053. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous